{"title":"Celgene支付1亿美元购买Acetylon的选择权，并与Array BioPharma合作","authors":"Heather Cartwright","doi":"10.3833/PDR.V2013I8.1971","DOIUrl":null,"url":null,"abstract":"Celgene has agreed to pay Acetylon Pharmaceuticals US$100 M upfront in order to obtain an exclusive option to buy the company at a future date for at least US$500 M and potentially more than US$1.6 B. Acetylon will use the non-dilutive funding to advance its portfolio of selective HDAC (histone deacetylase) inhibitors, including its Phase I/II candidate ACY-1215 (rocilinostat) for multiple myeloma. Celgene has also formed a global R&D collaboration with Array BioPharma focused on a preclinical development programme targeting a novel inflammation pathway.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2013-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Celgene Pays US$100 M for Option to Buy Acetylon and Partners with Array BioPharma\",\"authors\":\"Heather Cartwright\",\"doi\":\"10.3833/PDR.V2013I8.1971\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Celgene has agreed to pay Acetylon Pharmaceuticals US$100 M upfront in order to obtain an exclusive option to buy the company at a future date for at least US$500 M and potentially more than US$1.6 B. Acetylon will use the non-dilutive funding to advance its portfolio of selective HDAC (histone deacetylase) inhibitors, including its Phase I/II candidate ACY-1215 (rocilinostat) for multiple myeloma. Celgene has also formed a global R&D collaboration with Array BioPharma focused on a preclinical development programme targeting a novel inflammation pathway.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"17 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-10-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/PDR.V2013I8.1971\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2013I8.1971","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Celgene Pays US$100 M for Option to Buy Acetylon and Partners with Array BioPharma
Celgene has agreed to pay Acetylon Pharmaceuticals US$100 M upfront in order to obtain an exclusive option to buy the company at a future date for at least US$500 M and potentially more than US$1.6 B. Acetylon will use the non-dilutive funding to advance its portfolio of selective HDAC (histone deacetylase) inhibitors, including its Phase I/II candidate ACY-1215 (rocilinostat) for multiple myeloma. Celgene has also formed a global R&D collaboration with Array BioPharma focused on a preclinical development programme targeting a novel inflammation pathway.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
